From AI ambition to real world impact
Why data foundations matter more than ever
Artificial intelligence is already embedded in how life sciences organisations think about commercial strategy. From more precise targeting to faster insight generation and personalised engagement at scale, AI plays a central role in how teams plan, execute and optimise performance.
What is becoming increasingly clear, however, is that the impact of AI is shaped less by the sophistication of the algorithms themselves and more by the strength of the data that underpins them. As organisations move beyond pilots and point solutions, attention is naturally shifting to the foundations that allow AI to perform consistently, credibly and at scale.
Why data readiness matters more than algorithms
AI models learn patterns, detect signals and generate predictions based on the data they ingest. When that data is reliable, consistent and contextualised, AI can support confident decision‑making across launch planning, targeting and omnichannel execution.
When data is incomplete, fragmented or difficult to integrate, however, teams spend more time reconciling sources and validating outputs than acting on insights. This additional effort on data teams and resources is counterproductive to the goal of introducing AI. This is not an inherent issue with the AI system, itself—AI is only as capable as the data it leverages. It instead reflects the reality of evolving data environments that have been built over time for different purposes.
Recent industry research highlights the same challenges across the life sciences landscape. Organisations are adopting AI steadily, but consistent, well‑integrated data remains the primary barrier to scaling its value. The biggest data capability issues reported in our Digital Disruption survey was norming and integrating data from multiple sources, and analysing complex datasets. These findings mirror the challenges commercial teams face when working across claims, specialty, reference and program data.
The organisations seeing the greatest return from AI are those investing in robust data frameworks that reduce friction, build trust and support downstream analytics. In that context, data readiness becomes a strategic accelerator beyond a technical prerequisite.
AI-ready healthcare data
Moving from pilot programs and selective use to enterprise‑scale AI holds significant potential return on investment for biopharmaceutical sponsors. To ensure this expansion is efficient—and to support ROI—it requires data that is designed to support modern analytics from the outset.
AI‑ready healthcare data shares several characteristics:
- Accurate, refreshed frequently and stable over time, enabling longitudinal analysis rather than isolated snapshots
- Standardised and harmonised, using consistent definitions and coding frameworks so models can be trained and deployed confidently across use case
- Connected, linking patient‑level activity across claims, reference data, specialty channels and relevant programmes to provide essential context
- Accessible and interoperable, delivered in formats that integrate smoothly into cloud platforms and machine‑learning workflows
- Transparent, with clear provenance, documented limitations and strong governance help sustain trust in AI outputs as models move into production and inform strategic decisions
These data attributes are the result of deliberate strategy, thoughtful integration and sustained focus on quality and governance.
Data integration enables AI at scale
Across the pharmaceutical and clinical research ecosystems, there is growing consensus that standardised, connected data is one of the most important enablers of AI at scale.
Fragmented datasets force teams into repeated cycles of cleansing and reconciliation that slow insight generation and undermine confidence. Unified foundations remove those bottlenecks and allow AI initiatives to progress with speed and consistency.
This is as much a strategic consideration as a technical one. Organisations that invest early in harmonised, interoperable data are better positioned to operationalise AI across brands, markets and channels. The result is not just faster analytics, but more resilient AI programs that continue to deliver value as complexity increases.
Integrated, privacy-first linkage through Synoma®
Unlocking AI’s full potential depends on connected data. Synoma®, Symphony Health’s privacy‑preserving linkage solution, enables secure integration across healthcare and consumer datasets, creating longitudinal patient views that are essential for advanced analytics and predictive modelling.
With validated patient match rates exceeding 95% and decades of data integration expertise behind it, Synoma® transforms fragmented inputs into a unified, AI‑ready foundation. This allows biopharmaceutical sponsors and other life sciences organisations to train models with confidence, maintain privacy protections and scale commercial AI initiatives without compromising data integrity.
Designed for modern AI workflows
Symphony Health delivers curated datasets that are cloud‑ready and structured specifically for advanced analytics. Data is available in ML‑friendly formats such as Snowflake, as well as Parquet and CSV, enabling seamless integration into existing data lakes and pipelines.
Each dataset includes full lineage, consistent timestamps and pre‑derived measures aligned to common commercial use cases, such as treatment sequences, adherence metrics and NBRx signals. By reducing the time spent on data wrangling and preparation, Symphony enables teams to move more quickly from ingestion to insight.
Building the backbone for scalable AI
AI will continue to reshape how life sciences organisations operate. Its ability to scale, however, will always depend on the quality, connectivity and readiness of the data behind it. Strong data foundations create the conditions in which AI can deliver reliable insight, earn trust and support confident decision‑making across the organisation.
Symphony Health provides that foundation. Through harmonised, transparent and interoperable data designed for modern analytics, it enables life sciences companies to turn AI ambition into sustainable, enterprise‑level impact.
To learn more about how ICON and Symphony Health can support your AI readiness, connect with us today.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
- mHealth wearables
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Decoding AI in software as a medical device (SaMD)
- Software as a medical device (SaMD)
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Accelerating clinical development through DHTs
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
- Representation and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Prioritising patient-centred research for regulatory approval
-
Accelerating clinical development through DHTs
-
Regulatory Intelligence
-
Accelerating access
-
Meeting requirements for Joint Clinical Assessments
-
Navigating the regulatory landscape in the US and Japan:
-
Preparing for ICH GCP E6(R3) implementation
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
Exploring FDA guidance for modern Data Monitoring Committees
-
Streamlining dossier preparation
-
Accelerating access
-
Therapeutics insights
-
Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
-
Central Nervous System
-
A mind for digital therapeutics
-
Challenges and opportunities in traumatic brain injury clinical trials
-
Challenges and opportunities in Parkinson’s Disease clinical trials
-
Early, precise and efficient; the methods and technologies advancing Alzheimer’s and Parkinson’s R&D
-
Key Considerations in Chronic Pain Clinical Trials
-
ICON survey report: CNS therapeutic development
-
A mind for digital therapeutics
-
Glycomics
- Infectious Diseases
- NASH
- Obesity
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Endocrine and Metabolic Disorders
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Demystifying the Systematic Literature Reviews
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
From bottlenecks to breakthroughs
-
Linguistic validation of Clinical Outcomes Assessments
-
More than monitoring
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
-
Blended solutions insights
-
Clinical trials in Japan: An enterprise growth and management strategy
-
How investments in supply of CRAs is better than competing with the demand for CRAs
-
The evolution of FSP: not just for large pharma
-
Embracing a blended operating model
-
Observations in outsourcing: Survey results show a blended future
-
Clinical trials in Japan: An enterprise growth and management strategy
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Integrating openness and precision for competitive advantage
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel